# Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia

> **NCT00003746** · PHASE3 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 100 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** 2-chlorodeoxyadenosine (CDA) daily
- **DRUG:** 2-chlorodeoxyadenosine weekly

## Key facts

- **NCT ID:** NCT00003746
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2005-11
- **Final completion:** 2010-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2012-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003746, "Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00003746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*